Pharmaceuticals Global On demand · 24-48h

Global Drug Abuse Testing Products Market Strategic Research Report

Global Drug Abuse Testing Products Market Strategic Research…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Drug Abuse Testing Products Market
$10.2B2025
8.6%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Analyzers, Rapid Testing Devices, Consumables

By Application: Workplaces and Schools, Criminal Justice Systems and Law Enforcement Agencies, Hospitals, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Biomedical Diagnostics, BioMerieux, Abbott Laboratories, Bio-Rad, Dako, DiaSorin, Eiken, Fujirebio, Beckman Coulter, Siemens, F. Hoffmann-La Roche Ltd. (Genentech Inc.), Laboratory Corporation Of America Holdings, Danaher Corporation, Express Diagnostics International Inc, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc, Drgerwerk Ag & Co., Kgaa

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 125 pages
Market size 2025
$10.2B
Billion USD
Forecast CAGR
8.6%
2025-2032
Forecast 2032
$18.2B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

نظرة عامة

Scope of the Report

The global Drug Abuse Testing Products market size is predicted to grow from US$ 10,200 million in 2025 to US$ 17,930 million in 2032; it is expected to grow at a CAGR of 8.6% from 2026 to 2032.

Drug abuse test is a non-invasive technical analysis of biological samples such as blood, hair, urine, and others, to diagnose the presence of illegal, prescription drugs, or their metabolites. Among these urine testing is the most preferred sample type used for drugs of abuse testing. Drug testing offers a critical adjunct to clinical care and substance use. Drug testing is now increasingly being used by sports organizations, employers, forensic purposes, and several other applications.

The surge in number of people who consume alcohol and illicit drugs such as marijuana, cocaine, and others, is one of the major drivers for the drug abuse testing market. In addition, technological advancements in drug screening/testing devices and stringent government regulations mandating drug screening boost the market growth. However, lack of awareness and consideration of drug testing as a breach of privacy rights in certain countries restrict the growth of the global drug abuse testing market. Emerging markets such as the Asia-Pacific and LAMEA, provide lucrative opportunities for the drug abuse testing market growth.

This report presents a comprehensive overview of the global Drug Abuse Testing Products market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Analyzers
  • Rapid Testing Devices
  • Consumables

Segment by Application

  • Workplaces and Schools
  • Criminal Justice Systems and Law Enforcement Agencies
  • Hospitals
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Drug Abuse Testing Products market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Workplaces and Schools, Criminal Justice Systems and Law Enforcement Agencies, Hospitals evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Drug Abuse Testing Products Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 8.6%
Regional growth momentum
Market share by segment
Key metrics
Base value
$10.2B
2025
Forecast
$18.2B
2032
CAGR
8.6%
2025–2032
Regions
5
global
Key companies
Biomedical DiagnosticsBioMerieuxAbbott LaboratoriesBio-RadDakoDiaSorinEikenFujirebio
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
AnalyzersRapid Testing DevicesConsumables
By Application
Workplaces and SchoolsCriminal Justice Systems and Law Enforcement AgenciesHospitalsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Analyzers
  • 3.1.3 Rapid Testing Devices
  • 3.1.4 Consumables
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Workplaces and Schools
  • 4.1.3 Criminal Justice Systems and Law Enforcement Agencies
  • 4.1.4 Hospitals
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Biomedical Diagnostics
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 BioMerieux
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Abbott Laboratories
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Bio-Rad
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Dako
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 DiaSorin
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Eiken
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Fujirebio
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Beckman Coulter
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Siemens
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 F. Hoffmann-La Roche Ltd. (Genentech Inc.)
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Laboratory Corporation Of America Holdings
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Danaher Corporation
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Express Diagnostics International Inc
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Quest Diagnostics Incorporated
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Thermo Fisher Scientific Inc
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Drgerwerk Ag & Co.
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Kgaa
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Drug Abuse Testing Products market?
The global Drug Abuse Testing Products market is estimated at US$ 10.2 billion in 2025 (base year) and is projected to reach US$ 17.93 billion by 2032.
What is the forecast CAGR for the Drug Abuse Testing Products market?
The market is expected to grow at a CAGR of 8.6% from 2026 to 2032, expanding from US$ 10.2 billion in 2025 to US$ 17.93 billion in 2032, roughly 1.8 times its base-year value.
What is Drug Abuse Testing Products?
Drug abuse test is a non-invasive technical analysis of biological samples such as blood, hair, urine, and others, to diagnose the presence of illegal, prescription drugs, or their metabolites. Among these urine testing is the most preferred sample type used for drugs of abuse testing. Drug testing offers a critical adjunct to clinical care and substance use.
What are the main segments of the Drug Abuse Testing Products market by type?
By type, the market is segmented into Analyzers, Rapid Testing Devices and Consumables.
Which applications drive demand in the Drug Abuse Testing Products market?
Key applications covered include Workplaces and Schools, Criminal Justice Systems and Law Enforcement Agencies, Hospitals and Others.
Who are the key players in the Drug Abuse Testing Products market?
Key players profiled include Biomedical Diagnostics, BioMerieux, Abbott Laboratories, Bio-Rad, Dako, DiaSorin, Eiken and Fujirebio, among 18 companies covered in total.
Which regions and countries are covered for Drug Abuse Testing Products?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Drug Abuse Testing Products market report?
The report is intended for manufacturers and solution providers, distributors and end users in Workplaces and Schools, Criminal Justice Systems and Law Enforcement Agencies and Hospitals, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Drug Abuse Testing Products market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from ‏3,500.00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.